On September 22, 2020, Krishna Polu, M.D., Executive Vice President Research & Development and Chief Medical Officer of Equillium, Inc., notified the Company of his decision to resign from his position, which the Company and Dr. Polu have agreed will become effective December 31, 2020. During his tenure, Dr. Polu has provided leadership to the Company on its clinical programs and has built a capable, experienced clinical development team. Through the end of the year, Dr. Polu will continue to provide guidance and oversight of the Company’s development programs and will assist the board of directors and leadership team in identifying a suitable successor. Dr. Polu and the Company have entered into a consulting agreement, effective January 1, 2021, whereby Dr. Polu will help provide transitional support to his successor and assist the Company in the conduct of its business as reasonably requested by the Company. The Company’s board of directors is undertaking a search to identify the best candidate to succeed Dr. Polu.